Gregory Mattingley, MD
Psychiatry · Saint Charles, MONPI 1215933379
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,068,740 of the $4,712,274 with a category attached, or 65.1%. It is spread thinly across 53 manufacturers, the largest accounting for just 15.1%. Among psychiatry clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 4,680 payments — averaging $1006.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$713K
- AbbVie$581K
- Axsome Therapeutics, Inc.$516K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$448K
- Neurocrine Biosciences, Inc.$424K
- H. Lundbeck A S$411K
- plus $1.6M from 47 others
Across 625 payments — averaging $5588.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sage Therapeutics, LLC$884K
- Corium, LLC$726K
- Janssen Research & Development, LLC$481K
- AbbVie$322K
- Supernus Pharmaceuticals, Inc.$315K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$112K
- plus $653K from 20 others
What the payments were for
- Consulting fees$970,96621%
- Speaking & faculty fees$3,068,74065%
- Travel & lodging$582,76812%
- Food & beverage$82,1152%
- Education$7,6850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$613,820
- VRAYLAR$540,570
- Auvelity$458,026
- CAPLYTA$442,840
- INGREZZA$419,094
- ARISTADA$391,636
- ABILIFY MAINTENA$380,599
- LYBALVI$338,968
- BRINTELLIX$240,373
- QELBREE$202,841
- SPRAVATO$149,353
- ARISTADA INITIO$85,707
- ABILIFY ASIMTUFII$82,698
- COBENFY$74,769
- Dayvigo$65,886
- Azstarys$52,348
- SUNOSI$50,700
- VYVANSE$45,495
- Xelstrym$44,518
- JORNAY PM$44,423
How this compares
$4,712,274 in reported general payments places this provider in the 95th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $108,866 |
| AtivanLorazepam | 11 | $95,226 |
| AristadaAripiprazole Lauroxil | 25 | $74,740 |
| VraylarCariprazine Hcl | 37 | $41,625 |
| CaplytaLumateperone Tosylate | 20 | $40,492 |
| Abilify MaintenaAripiprazole | 14 | $40,341 |
| RexultiBrexpiprazole | 22 | $39,306 |
| AuvelityDextromethorphan Hbr/Bupropion | 26 | $35,573 |
| TrintellixVortioxetine Hydrobromide | 56 | $31,608 |
| VyvanseLisdexamfetamine Dimesylate | 73 | $29,165 |
| Lisdexamfetamine Dimesylate | 55 | $12,119 |
| Aripiprazole | 108 | $11,943 |
| Chlorpromazine Hcl | 17 | $11,479 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 138 | $10,911 |
| Atomoxetine Hcl | 46 | $7,088 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $424,024 | $108,86613 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $713,087 | $79,64736 claims |
| Alkermes, Inc.Aristada | $203,107 | $74,74025 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $82,046 | $60,773129 claims |
| AbbVieVraylar | $580,903 | $41,62537 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $447,617 | $40,49220 claims |
| Axsome Therapeutics, Inc.Auvelity | $516,066 | $35,57326 claims |
| MerckBelsomra | $13 | $4,91812 claims |
| Eisai Inc.Dayvigo | $66,297 | $4,49812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Saint Charles
- Howard IlivickySaint Charles$24K
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- Brian BarashKansas City$856K
- Casey ProughLees Summit$615K
- George GrossbergSaint Louis$501K
- Shahid InsafBranson$416K
- Ahmed TaranissiMexico$343K
- Ravdeep KhanujaPoplar Bluff$310K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.